NASDAQ
0.40USD
-0.02 (-5.61%)
We have scored 3 news catalysts on Enlivex Therapeutics Ltd. (ENLV) over the past 12 months. The biggest single-day move next to one of them came Nov 24, 2025, when ENLV closed +13.8%: “Enlivex Announces $212,000,000 Private Placement to Initiate World's First Prediction Markets Digital Asset Treasury Strategy, via RAIN token Accumulation, and the Appointment of Matteo Renzi, Former Prime Minister of Italy, to its Board”. Coverage across the window leans positive (average ticker sentiment +0.33). Most of the impact sits in interest rate sensitivity duration and floating rate debt ratio.
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
6.7M
P/E
—
EPS
—
Beta
1.42
52W range
0.3801-27.15
Day range
0.38–0.43
Open
0.42
Prev close
0.42
Volume
614.7K
Avg volume
266.3K
Dividend
0.00
IPO
2014-07-31
Daily OHLCV with SMA overlays and session pivots. Draw your levels and trendlines on it, or ask the AI analyst what the price is reacting to.
Suppliers, customers, partners and competitors, derived from what the news actually says about Enlivex Therapeutics Ltd. — not a sector bucket. Click an edge to see the articles that established the link.
Latest scored catalyst for ENLV: .
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Enlivex Therapeutics Ltd., established in 2005 and based in Nes Ziona, Israel, operates as a clinical-stage biotechnology firm dedicated to macrophage reprogramming immunotherapy. The company is currently advancing Allocetra, its flagship cell-based therapeutic. This treatment is undergoing Phase II clinical evaluation for its effectiveness in addressing organ dysfunction and failure that arises from sepsis. Additionally, Allocetra is being investigated in preclinical studies for its potential application in solid tumor therapy.
